Clinical Research Directory

Inclusion Criteria: * Evidence of symptomatic obstructive peripheral arterial disease. * All-comer patients undergoing endovascular lower-limb revascularization with Supera® stent implantation in the superficial femoral (SFA) or popliteal arteries. * Patient or legal representative understand the SupPORT registry procedures, and have voluntarily provided informed written consent regarding their participation. * Participant is willing to remain in the SupPORT Registry for at least 1 year. * Target lesion is a primary atherosclerotic lesion or a restenosis occurring in a non-stented of the SFA or the popliteal artery, distancing at least ≥ 1 cm from any previously implanted vascular stent. * Target lesion causes a ≥50% arterial obstruction (visually confirmed on digital subtraction angiography). Exclusion Criteria: * • Any contraindication for peri-interventional or post-interventional anti-thrombotic therapy (including, but not restricted to Non-fractioned heparina, low-molecular weight heparina \[LMWH\], Clopidogrel, Ticagrelol, Ticlopidine, Acetylsalicylic acid, dipiridamol, direct thrombin \[factor II\] or factor Xa inhibitors, vitamin-K antagonists). * Participation in other research study that may influence obtained results. * Pregnant or breastfeeding women, or expected pregnancy to occur during the study period. * Treatment of intrastent restenosis/occlusion of previous peripheral vascular stent. * Non-corrected hemodynamically significant obstructive arterial disease of the ipsilateral inflow arteries (aorta, iliac arteries)